Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Adaptimmune Therapeutics plc , a leader in cell therapy to treat cancer, today announced the completion of the submission of its rolling Biologics License Application to the U.S. Food and Drug...

Related Keywords

United States ,Philadelphia ,Pennsylvania ,America ,Julip Miller ,Dana Lynch ,Brandi Felser ,Adrian Rawcliffe ,Exchange Commission ,Corporate Communications ,Drug Administration ,Connective Tissue Oncology Society ,Sarcoma Foundation Of America ,Nasdaq ,Corporate Affairs ,United Newsfile Corp ,Biologics License Application ,Priority Review ,Chief Executive Officer ,Sarcoma Foundation ,Orphan Drug Designation ,Regenerative Medicine Advanced Therapy ,Orthop Surg ,Hong Kong ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Senior Director ,Markets ,